NCT03148769

Brief Summary

Bacteremia The Hypothesis of the study are the followings:

  • To demonstrate relevant epidemiologic and clinical changes with potentially impact in the management and prognosis of the patients with bacteremia.
  • Since the diagnosis and management is heterogeneous between centers, we could identify a scenario to improve.
  • To identify quality indicators in the management of bacteremia.
  • To demonstrate that some interventions made by Bacteremia Team pose relevant impact in the prognosis of bacteremia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,320

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2016

Typical duration for all trials

Geographic Reach
1 country

29 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 5, 2017

Completed
26 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 11, 2017

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

May 21, 2019

Status Verified

May 1, 2019

Enrollment Period

7 months

First QC Date

April 5, 2017

Last Update Submit

May 20, 2019

Conditions

Keywords

Bloodstream infections, epidemiology

Outcome Measures

Primary Outcomes (1)

  • Epidemiology and prognostic factors of bacteremia episodes.

    * Global incidence and per type of acquisition. * Global etiology and per type of acquisition. * Frequency of multiresistant and emerging microorganism. * Source of bacteremia. * Clinical severity of presentation. * Clinical failure, mortality at day 7, mortality at day 30, recurrence, length of stay and re-admission at hospital.

    From day 0 to day 30

Secondary Outcomes (6)

  • Clinical management of patients with bacteremia during the episode.

    From day 0 to day 30

  • Differences in the management between types of services, wards and hospitals.

    From day 0 to day 30

  • Influence of clinical management in the prognosis.

    From day 0 to day 30

  • Developing and validating a predictive model for early and late mortality.

    From day 0 to day 30

  • Quality indicators in the management of bacteremia.

    From day 0 to day 30

  • +1 more secondary outcomes

Eligibility Criteria

Age13 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

It will be included all episodes of bacteremia diagnosed over a year in all participating hospitals in patients over 13 years old. It´s no possible to make a calculation of the sample size, this will depend on the type of hospital, the number of beds of the same and the number of blood cultures that are requested during the period of recruitment of the study.

You may qualify if:

  • Every episode of bacteremia in patients older than 13 years old, confirmed microbiologically and clinically significant (presence of clinical sepsis data at diagnosis) should be prospectively included on the basis of standard criteria.
  • Episodes of transient bacteremia may be included.
  • Drugs will be prescribed in the usual way, according to the conditions established in the authorization. The assignment of a patient to a particular therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice, and the decision to prescribe a particular drug will be clearly dissociated from the decision to include to the patient in the study.

You may not qualify if:

  • Bacteremias without clinical relevance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Public Health Agency Business Hospital de Poniente.

El Ejido, Almería, 04700, Spain

Location

General Hospital of Granollers

Granollers, Barcelona, 08402, Spain

Location

University Hospital Mútua de Terrasa

Terrassa, Barcelona, 08221, Spain

Location

Hospital Punta Europa

Algeciras, Cádiz, 11207, Spain

Location

Jerez de la Frontera Hospital

Jerez de la Frontera, Cádiz, 11138, Spain

Location

Hospital San Juan de la Cruz

Úbeda, Jaen, 23400, Spain

Location

Hospital El Bierzo

Ponferrada, León, 24404, Spain

Location

Costa del Sol Hospital

Márbella, Málaga, 29603, Spain

Location

University Hospital of Vigo

Vigo, Pontevedra, 36204, Spain

Location

University General Hospital of Alicante

Alicante, 03012, Spain

Location

Torrecárdenas Hospital

Almería, 04009, Spain

Location

L´ Esperit Sant ( Santa Coloma Granemet) Hospital

Barcelona, 08923, Spain

Location

University Hospital of Burgos

Burgos, 09006, Spain

Location

University Hospital Puerta del Mar

Cadiz, 11009, Spain

Location

La Linea de la Concepción Hospital

Cadiz, 11300, Spain

Location

Puerto Real Hospital

Cadiz, 11510, Spain

Location

University Hospital Reina Sofía

Córdoba, 14004, Spain

Location

University Hospital San Cecilio

Granada, 18012, Spain

Location

University Hospital Virgen de las Nieves

Granada, 18014, Spain

Location

Ciudad de Jaén Hospital

Jaén, 23007, Spain

Location

University Hospital of León

León, 24001, Spain

Location

University Hospital Arnau de Vilanova

Lleida, 25198, Spain

Location

University Hospital Carlos Haya ( Málaga)

Málaga, 29010, Spain

Location

Central University Hospital of Asturias

Oviedo, 33011, Spain

Location

University Clinic of Navarra

Pamplona, 31008, Spain

Location

University Hospital Marqués de Valdecilla

Santander, 30008, Spain

Location

University Hospital Virgen Macarena

Seville, 41009, Spain

Location

University Virgen de Valme Hospital

Seville, 41014, Spain

Location

Universitary Hospital Cruces

Vizcaya, 48903, Spain

Location

Related Publications (17)

  • Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003 Dec;31(12):2742-51. doi: 10.1097/01.CCM.0000098031.24329.10.

  • Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. doi: 10.1097/01.ccm.0000194725.48928.3a.

  • Rodriguez-Bano J, Lopez-Prieto MD, Portillo MM, Retamar P, Natera C, Nuno E, Herrero M, del Arco A, Munoz A, Tellez F, Torres-Tortosa M, Martin-Aspas A, Arroyo A, Ruiz A, Moya R, Corzo JE, Leon L, Perez-Lopez JA; SAEI/SAMPAC Bacteraemia Group. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect. 2010 Sep;16(9):1408-13. doi: 10.1111/j.1469-0691.2009.03089.x.

  • Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J, Bereciartua-Bastarrica E, Farinas MC, Sanz-Franco M, Natera C, Corzo JE, Lomas JM, Pasquau J, Del Arco A, Martinez MP, Romero A, Muniain MA, de Cueto M, Pascual A, Rodriguez-Bano J; REIPI/SAB group. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis. 2013 Nov;57(9):1225-33. doi: 10.1093/cid/cit499. Epub 2013 Aug 8.

  • Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.

  • Rodriguez-Bano J, Pano-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, Cisneros JM, Cobo J, Delgado O, Garnacho-Montero J, Grau S, Horcajada JP, Hornero A, Murillas-Angoiti J, Oliver A, Padilla B, Pasquau J, Pujol M, Ruiz-Garbajosa P, San Juan R, Sierra R; Grupo de Estudio de la Infeccion Hospitalaria-Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica; Sociedad Espanola de Farmacia Hospitalaria; Sociedad Espanola de Medicina Preventiva, Salud Publica e Higiene. [Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document]. Enferm Infecc Microbiol Clin. 2012 Jan;30(1):22.e1-22.e23. doi: 10.1016/j.eimc.2011.09.018. Epub 2011 Dec 15. Spanish.

  • Mosier MJ, Ton-That H. Making the case for de-escalation therapy in ventilator-associated pneumonia once again. Crit Care Med. 2013 Jul;41(7):1810-1. doi: 10.1097/CCM.0b013e31828ce949. No abstract available.

  • Kaye KS. Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia. J Hosp Med. 2012;7 Suppl 1:S13-21. doi: 10.1002/jhm.983.

  • Gaynes R. Health care--associated bloodstream infections: a change in thinking. Ann Intern Med. 2002 Nov 19;137(10):850-1. doi: 10.7326/0003-4819-137-10-200211190-00015. No abstract available.

  • Cisneros-Herreros JM, Sanchez-Gonzalez M, Prados-Blanco MT, Llanos-Rodriguez C, Vigil-Martin E, Soto-Espinosa de los Monteros B, Pachon-Diaza J. [Blood cultures in the emergency department]. Enferm Infecc Microbiol Clin. 2005 Mar;23(3):135-9. doi: 10.1157/13072162. Spanish.

  • Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005 Apr 7;352(14):1436-44. doi: 10.1056/NEJMoa043252.

  • Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, Perez-Cano R, Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004 Mar;42(3):1089-94. doi: 10.1128/JCM.42.3.1089-1094.2004.

  • Al-Hasan MN, Juhn YJ, Bang DW, Yang HJ, Baddour LM. External validation of bloodstream infection mortality risk score in a population-based cohort. Clin Microbiol Infect. 2014 Sep;20(9):886-91. doi: 10.1111/1469-0691.12607. Epub 2014 Mar 26.

  • Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013 Oct;19(10):948-54. doi: 10.1111/1469-0691.12085. Epub 2012 Nov 27.

  • Retamar P, Portillo MM, Lopez-Prieto MD, Rodriguez-Lopez F, de Cueto M, Garcia MV, Gomez MJ, Del Arco A, Munoz A, Sanchez-Porto A, Torres-Tortosa M, Martin-Aspas A, Arroyo A, Garcia-Figueras C, Acosta F, Corzo JE, Leon-Ruiz L, Escobar-Lara T, Rodriguez-Bano J; SAEI/SAMPAC Bacteremia Group. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8. doi: 10.1128/AAC.00462-11. Epub 2011 Oct 17.

  • Retamar P, Lopez-Prieto MD, Natera C, de Cueto M, Nuno E, Herrero M, Fernandez-Sanchez F, Munoz A, Tellez F, Becerril B, Garcia-Tapia A, Carazo I, Moya R, Corzo JE, Leon L, Munoz L, Rodriguez-Bano J; Sociedad Andaluza de Enfermedades Infecciosas/Sociedad Andaluza de Microbiologia y Parasitologia Clinica and Red Espanola de Investigacion en Enfermedades Infecciosas (SAEI/SAMPAC/REIPI) Bacteremia Group; Rodriguez-Lopez F, Garcia MV, Fernandez-Galan V, del Arco A, Perez-Santos MJ, Sanchez Porto A, Torres-Tortosa M, Martin-Aspas A, Arroyo A, Garcia-Figueras C, Acosta F, Florez C, Navas P, Escobar-Lara T. Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis. 2013 Jul 24;13:344. doi: 10.1186/1471-2334-13-344.

  • Retamar P, Lopez-Prieto MD, Rodriguez-Lopez F, de Cueto M, Garcia MV, Gonzalez-Galan V, Del Arco A, Perez-Santos MJ, Tellez-Perez F, Becerril-Carral B, Martin-Aspas A, Arroyo A, Perez-Cortes S, Acosta F, Florez C, Leon-Ruiz L, Munoz-Medina L, Rodriguez-Bano J; SAEI/SAMPAC/REIPI Bacteremia Group. Predictors of early mortality in very elderly patients with bacteremia: a prospective multicenter cohort. Int J Infect Dis. 2014 Sep;26:83-7. doi: 10.1016/j.ijid.2014.04.029. Epub 2014 Jul 5.

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Microbial strains

MeSH Terms

Conditions

BacteremiaSepsis

Condition Hierarchy (Ancestors)

Bacterial InfectionsBacterial Infections and MycosesInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jesús Rodríguez-Baño, MD PhD

    Unidad Clínica de Enfermedades Infecciosas, Microbiología. Hospital Universitario Virgen Macarena

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2017

First Posted

May 11, 2017

Study Start

October 1, 2016

Primary Completion

May 1, 2017

Study Completion

May 1, 2019

Last Updated

May 21, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will share

Locations